Experience of the Izmir Pediatric Oncology Group on neuroblastoma: IPOG-NBL-92 protocol

Pediatric Hematology and Oncology

Volumn 20, Issue 3, 2003, Pages 211-218

  Olgun, Nur ^a   Kansoy, Savaş ^b   Aksoylar, Serap ^b,e   Cetingul, Nazan ^b   Vergin, Canan ^c   Oniz, Haldun ^d   Sarialioglu, Faik ^a   Kantar, Mehmet ^b   Uysal, Kamer ^a   Tuncyurek, Müge ^b   Kargi, Aydanur ^a   Aktas, Safiye ^c   Bayol, Ümit ^d   Karaca, Irfan ^c   Arikan, Ahmet ^d   Balik, Erol ^b   Aktug, Tanju ^a   Elmas, Nevra ^b   Kovanlikaya, Arzu ^a   Kinay, Münir ^a   Anacak, Yavuz ^b   Degirmenci, Berna ^a   Burak, Zeynep ^b   more..

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c DR BEHÇET UZ CHILDREN'S HOSPITAL   (Turkey)

^d SSK Tepecik Teaching Hospital   (Turkey)

^e NONE   (Turkey)

Author keywords

Cancer in Turkey; Childhood; Neuroblastoma; Treatment

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; MELPHALAN; NEURON SPECIFIC ENOLASE; VINCRISTINE;

ABDOMINAL CANCER; AGE DISTRIBUTION; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG FATALITY; ENZYME BLOOD LEVEL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; INFANT; LACTATE DEHYDROGENASE BLOOD LEVEL; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NEUROBLASTOMA; SIDE EFFECT; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TURKEY (REPUBLIC);

EID: 1642501025     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010390158838     Document Type: Article

References (10)

1. Brodeur GM, Castleberry RP. Neuroblastoma. In: Pizzo P, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott-Raven; 1997;761-789.
2. Castleberry RP. Biology and treatment of neuroblastoma. Pediatr Clin North Am. 1997;44:919-937.
3. German Cooperative Trial Neuroblastoma-90; 1990.
4. Matthay KK, Atkinson JB, Stram DO, et al. Pattern of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Children's Cancer Group pilot study. J Clin Oncol. 1993;11:2226-2233.
5. Wolden SL, Gollamudi SV, Kushner BH, et al. Local control with multimodality therapy for stage 4 neuroblastoma. Int J Radiat Oncol Biol Phys. 2000;46:969-974.
6. Rubie H, Plantaz D, Coze C, et al. Localized and unresectable neuroblastoma in infants: excellent outcome with primary chemotherapy. Med Pediatr Oncol. 2001;36:247-250.
7. Coldman AJ, Fryer CJH, Elwood JM, Sonly MJ. Neuroblastoma: influences of age at diagnosis, stage, tumour site, and gender on prognosis. Cancer 1980;46:1896-1901.
8. Berthold F, Treehow R, Utsch S, Zieschang J. Prognostic factors in metastatic neuroblastoma: multivariate analysis of 182 cases. Am J Pediatr Oncol. 1992;14:207-215.
9. Cotterill SJ, Pearson ADJ, Pritchard J, et al. Clinical prognostic factors in 1277 patients with neuroblastoma: results of the European Neuroblastoma Study Group 'survey' 1882-1992. Eur J Cancer. 2000;36:901-908.
10. Shuster JJ, McWilliams NB, Castleberry R, et al. Serum lactate dehydrogenase in childhood neuroblastoma: a Pediatric Oncology Group recursive partitioning study. Am J Clin Oncol. 1992;15:295-303.